ATE529098T1 - Feste arzneiform einer darmlöslichen dispersion und verfahren zur herstellung derselben - Google Patents

Feste arzneiform einer darmlöslichen dispersion und verfahren zur herstellung derselben

Info

Publication number
ATE529098T1
ATE529098T1 AT07015396T AT07015396T ATE529098T1 AT E529098 T1 ATE529098 T1 AT E529098T1 AT 07015396 T AT07015396 T AT 07015396T AT 07015396 T AT07015396 T AT 07015396T AT E529098 T1 ATE529098 T1 AT E529098T1
Authority
AT
Austria
Prior art keywords
producing
enteric
solid dispersion
same
disintegrant
Prior art date
Application number
AT07015396T
Other languages
English (en)
Inventor
Fumie Kusaki
Takafumi Hoshino
Naosuke Maruyama
Yuichi Nishiyama
Ikuo Fukui
Hiroshi Umezawa
Original Assignee
Shinetsu Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shinetsu Chemical Co filed Critical Shinetsu Chemical Co
Application granted granted Critical
Publication of ATE529098T1 publication Critical patent/ATE529098T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07015396T 2006-08-08 2007-08-06 Feste arzneiform einer darmlöslichen dispersion und verfahren zur herstellung derselben ATE529098T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006215401 2006-08-08
JP2006287860 2006-10-23

Publications (1)

Publication Number Publication Date
ATE529098T1 true ATE529098T1 (de) 2011-11-15

Family

ID=38520583

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07015396T ATE529098T1 (de) 2006-08-08 2007-08-06 Feste arzneiform einer darmlöslichen dispersion und verfahren zur herstellung derselben

Country Status (5)

Country Link
US (1) US8343548B2 (de)
EP (1) EP1886673B1 (de)
KR (1) KR101201554B1 (de)
AT (1) ATE529098T1 (de)
TW (1) TWI414321B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP5847813B2 (ja) * 2010-06-23 2016-01-27 シマベイ セラピューティクス， インコーポレーテッド ５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP2907508A1 (de) * 2014-02-14 2015-08-19 Shin-Etsu Chemical Co., Ltd. Hydroxyalkylalkyl-Cellulose zur Tablettierung und feste Zubereitung damit
MA39725B1 (fr) * 2014-03-14 2021-09-30 Les Laboratoires Servier Sas Compositions pharmaceutiques de composés thérapeutiquement actifs
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
EP3011956B1 (de) 2014-10-23 2018-12-26 Shin-Etsu Chemical Co., Ltd. Methyl zellulose zur verwendung in der tablettierung und die daraus gebildete feste zubereitungsform
JP6203702B2 (ja) * 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
WO2017015414A1 (en) 2015-07-23 2017-01-26 Zito Jr Arthur J Responsive dispersion from compartment in aqueous solution
FI3362065T3 (fi) 2015-10-15 2024-06-19 Servier Lab Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
KR102699521B1 (ko) 2015-10-15 2024-08-26 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US12408638B2 (en) 2018-01-19 2025-09-09 Arthur J. Zito, Jr. Responsive dispersion from compartment in aqueous solution
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
KR102173092B1 (ko) * 2018-11-20 2020-11-02 중앙대학교 산학협력단 루테인 장용성 고체분산체를 유효성분으로 함유하는 위산보호용 조성물 및 이를 포함하는 경구용 제제
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
WO2022061120A1 (en) * 2020-09-18 2022-03-24 Dispersol Technologies, Llc Solid dispersions containing amorphous nintedanib, their synthesis and use thereof
CN120983690B (zh) * 2025-10-21 2025-12-26 重庆大清医疗器械有限公司 一种可生物降解吸收的止血组合物及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4838858B1 (de) 1970-03-23 1973-11-20
US3852421A (en) 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
JPS5163927A (en) 1974-11-28 1976-06-02 Shinetsu Chemical Co Ketsugoseiryokonajozaihokaizaino seizohoho
US5028433A (en) * 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
HU209564B (en) 1991-01-30 1994-07-28 Egyt Gyogyszervegyeszeti Gyar Process for producing rapide tablets containing levodopa and carbidopa
DK0662320T3 (da) 1991-08-30 2001-09-24 Showa Pharm Chem Ind Tør gelsammensætning
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP2994956B2 (ja) 1994-05-31 1999-12-27 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、その組成物およびその錠剤
JP3001401B2 (ja) 1995-09-19 2000-01-24 信越化学工業株式会社 セルロースエーテルの粉末化方法およびセルロースエーテルの粉末化装置
AU717817B2 (en) 1996-06-06 2000-04-06 Bifodan A/S Enteric coating, comprising alginic acid, for an oral preparation
JP3408398B2 (ja) 1997-05-09 2003-05-19 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース粉末の製造方法
JP3718341B2 (ja) 1998-05-12 2005-11-24 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロースとその製造方法
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
EP1054019A1 (de) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Niedersubstituierte Hydroxypropylcellulose
JP2001009316A (ja) 1999-06-29 2001-01-16 Shin Etsu Chem Co Ltd パルプの粉末化方法及びセルロースエーテルの製造方法
US6680069B1 (en) 1999-11-09 2004-01-20 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose and process for manufacturing the same
KR100496749B1 (ko) * 2000-07-05 2005-06-22 아사히 가세이 가부시키가이샤 셀룰로스 분말
US7009046B2 (en) 2001-12-11 2006-03-07 Shin-Etsu Chemical Co. Ltd. Low-substituted hydroxypropyl cellulose and agent serving both as binder and disintegrant for dry direct compression
WO2003063831A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
TW200404544A (en) 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
JP2004067606A (ja) 2002-08-08 2004-03-04 Zensei Yakuhin Kogyo Kk イトラコナゾール経口投与製剤
KR100592511B1 (ko) 2002-12-30 2006-07-03 안경섭 벤즈이미다졸 유도체 또는 약리학적으로 허용되는 이의염을 활성물질로 하는 안정성이 강화된 방출제어형 제제및 그 제조방법
CN100563658C (zh) * 2003-11-14 2009-12-02 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
EP1854463A4 (de) 2005-03-03 2011-03-23 Takeda Pharmaceutical Zusammensetzung mit kontrollierter freisetzung
US8486450B2 (en) 2005-12-28 2013-07-16 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
US20100226979A1 (en) 2006-03-21 2010-09-09 Jubilant Organosys Limited Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate

Also Published As

Publication number Publication date
KR101201554B1 (ko) 2012-11-14
EP1886673A3 (de) 2009-11-04
TW200817051A (en) 2008-04-16
US20080038340A1 (en) 2008-02-14
TWI414321B (zh) 2013-11-11
EP1886673A2 (de) 2008-02-13
US8343548B2 (en) 2013-01-01
EP1886673B1 (de) 2011-10-19
KR20080013776A (ko) 2008-02-13

Similar Documents

Publication Publication Date Title
ATE529098T1 (de) Feste arzneiform einer darmlöslichen dispersion und verfahren zur herstellung derselben
ATE555776T1 (de) Feste arzneiform, die eine feste dispersion enthält, und verfahren zur herstellung derselben
JP7637616B2 (ja) 厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形
CN109475504B (zh) 剂型
WO2010053335A2 (ko) 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에 의해 제조된 분말 및 이를 포함하는 약학적 조성물
IL175072A (en) Controlled-release sterile injectable aripiprazole formulation containing 1 to 10 micron average-sized once or twice-a-month, including freeze-dried formulation, preparation, and use for the treatment of schizophrenia
JP2017533914A (ja) 胃内滞留性ゲル製剤
NZ610701A (en) Once daily formulation of lacosamide
WO2007116954A3 (en) Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
BRPI0716436B8 (pt) sistema de liberação controlada e método para fabricação do mesmo
JP2016500129A (ja) 多糖エステルミクロスフェア並びにそれに関する方法及び物品
EP2054042A4 (de) Verfahren zur herstellung von biologischen wirkstoffen in nanoteilchenform
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
WO2005112886A3 (en) Methods and articles for the delivery of therapeutic agents
WO2005117843A3 (en) Sustained release preparations
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
EP1847257A3 (de) Feste Zubereitung eine magensaftresistente Feststoff-Dispersion enthaltend
IL189667A (en) Derivatives of carboxylic acid 4 - amino - 3 {[(aryl / troaryl) - oxy] methyl} - thiano [c - 2, 3] pyridine - 7 - and pharmaceutical compounds containing them for the treatment of cancer
WO2006089674A3 (en) Tablets with improved drug substance dispersibility
DE60211769D1 (de) Verfahren zur Herstellung von Arzneistoffgranulatkörnern, die Arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische Zubereitungen
WO2006137855A3 (en) Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
EP4279137A3 (de) Orale pharmazeutische zusammensetzung und verfahren zur herstellung einer teilchenförmigen formulierung mit der zusammensetzung
HUE034511T2 (en) Solid dosage form with low viscosity hydroxyalkylcellulose content
WO2008039615A3 (en) Controlled release hydrogel formulation
DE602006000819D1 (de) Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties